{
  "total_claims_found": 32,
  "transcript_summary": "Johnson & Johnson reported strong 2025 results with $94.2 billion in revenue and provided 2026 guidance forecasting revenue to reach $100 billion.",
  "claims": [
    {
      "qualifiers": [
        "over"
      ],
      "quote_end_char": 3746,
      "quote_start_char": 3615,
      "metric_type": "other",
      "period": "FY 2025",
      "claimed_value": 32,
      "quote_text": "In 2025, we invested over $32 billion in R&D and M&A, including the acquisitions of Intracellular Therapies and Halda Therapeutics.",
      "speaker_role": "ceo",
      "confidence": 1,
      "gaap_classification": "unknown",
      "speaker": "Joaquin Duato",
      "unit": "dollars",
      "claimed_value_raw": "$32 billion",
      "metric_context": "Total",
      "claim_type": "absolute",
      "is_approximate": false,
      "claim_id": "claim_001",
      "scale": "billions"
    },
    {
      "scale": "ones",
      "period": "FY 2025",
      "quote_end_char": null,
      "gaap_classification": "gaap",
      "claim_id": "claim_002",
      "qualifiers": [],
      "claimed_value_raw": "5.3%",
      "metric_context": "Total",
      "speaker_role": "ceo",
      "unit": "percent",
      "quote_text": "Over the full year, we delivered 5.3% operational sales growth.",
      "metric_type": "revenue",
      "speaker": "Joaquin Duato",
      "claimed_value": 5.3,
      "quote_start_char": null,
      "comparison_period": "FY 2024",
      "is_approximate": false,
      "confidence": 1,
      "claim_type": "yoy_growth"
    },
    {
      "speaker": "Joaquin Duato",
      "quote_text": "In innovative medicine, we reported operational sales growth for the year of 5.3%.",
      "unit": "percent",
      "speaker_role": "ceo",
      "quote_start_char": 4957,
      "quote_end_char": 5039,
      "scale": "ones",
      "claimed_value": 5.3,
      "is_approximate": false,
      "confidence": 1,
      "comparison_period": "FY 2024",
      "metric_context": "Innovative Medicine",
      "claim_type": "yoy_growth",
      "qualifiers": [],
      "gaap_classification": "gaap",
      "period": "FY 2025",
      "metric_type": "revenue",
      "claim_id": "claim_003",
      "claimed_value_raw": "5.3%"
    },
    {
      "gaap_classification": "gaap",
      "quote_end_char": 5166,
      "speaker": "Joaquin Duato",
      "qualifiers": [
        "exceeded",
        "for the first time"
      ],
      "claim_type": "absolute",
      "confidence": 1,
      "quote_start_char": 5040,
      "is_approximate": false,
      "scale": "billions",
      "claimed_value": 60,
      "metric_context": "Pharmaceutical",
      "claimed_value_raw": "$60 billion",
      "metric_type": "revenue",
      "claim_id": "claim_004",
      "unit": "dollars",
      "speaker_role": "ceo",
      "quote_text": "Full-year sales for our Pharmaceutical business exceeded $60 billion for the first time, with 13 brands growing double digits.",
      "period": "FY 2025"
    },
    {
      "claimed_value_raw": "21%",
      "comparison_period": "FY 2024",
      "scale": "ones",
      "claimed_value": 21,
      "metric_type": "revenue",
      "claim_id": "claim_005",
      "period": "FY 2025",
      "speaker": "Joaquin Duato",
      "qualifiers": [],
      "quote_start_char": 5719,
      "gaap_classification": "gaap",
      "is_approximate": false,
      "quote_text": "In 2025, we delivered 21% operational sales growth, and we expect to exceed $50 billion in annual sales by 2030.",
      "metric_context": "Oncology",
      "claim_type": "yoy_growth",
      "unit": "percent",
      "speaker_role": "ceo",
      "quote_end_char": 5831,
      "confidence": 1
    },
    {
      "quote_text": "With annual sales over $14 billion, DARZALEX grew an impressive 22% across the full year.",
      "claim_id": "claim_007",
      "scale": "billions",
      "is_approximate": false,
      "metric_type": "revenue",
      "gaap_classification": "gaap",
      "quote_start_char": 6152,
      "unit": "dollars",
      "speaker": "Joaquin Duato",
      "qualifiers": [
        "over"
      ],
      "claimed_value": 14,
      "speaker_role": "ceo",
      "confidence": 1,
      "period": "FY 2025",
      "claimed_value_raw": "$14 billion",
      "quote_end_char": 6241,
      "metric_context": "DARZALEX",
      "claim_type": "absolute"
    },
    {
      "claim_type": "absolute",
      "unit": "dollars",
      "period": "FY 2025",
      "gaap_classification": "gaap",
      "metric_type": "revenue",
      "metric_context": "Tremfya",
      "quote_start_char": 8137,
      "qualifiers": [
        "more than",
        "for the first time"
      ],
      "confidence": 1,
      "claim_id": "claim_009",
      "quote_text": "And with global full-year sales of Tremfya accelerating to more than $5 billion for the first time, we're increasingly confident that Tremfya will exceed $10 billion in peak year sales.",
      "speaker": "Joaquin Duato",
      "scale": "billions",
      "claimed_value": 5,
      "is_approximate": false,
      "speaker_role": "ceo",
      "quote_end_char": 8322,
      "claimed_value_raw": "$5 billion"
    },
    {
      "quote_end_char": 8823,
      "comparison_period": "FY 2024",
      "qualifiers": [],
      "metric_type": "revenue",
      "confidence": 1,
      "unit": "percent",
      "claim_id": "claim_010",
      "claimed_value": 10,
      "speaker_role": "ceo",
      "claimed_value_raw": "10%",
      "quote_text": "Turning to neuroscience, where 2025 operational sales grew 10%.",
      "claim_type": "yoy_growth",
      "is_approximate": false,
      "quote_start_char": 8760,
      "scale": "ones",
      "period": "FY 2025",
      "metric_context": "Neuroscience",
      "speaker": "Joaquin Duato",
      "gaap_classification": "gaap"
    },
    {
      "gaap_classification": "gaap",
      "quote_text": "Spravato continues its strong trajectory with 57% growth in the year, with more than two hundred thousand patients now treated worldwide.",
      "quote_end_char": 8962,
      "claim_id": "claim_011,claim_type:",
      "comparison_period": "FY 2024",
      "unit": "percent",
      "claimed_value": 57,
      "speaker": "Joaquin Duato",
      "qualifiers": [],
      "speaker_role": "ceo",
      "claimed_value_raw": "57%",
      "period": "FY 2025",
      "scale": "ones",
      "quote_start_char": 8825,
      "metric_context": "Spravato",
      "confidence": 1,
      "claim_type": "yoy_growth",
      "is_approximate": false,
      "metric_type": "revenue"
    },
    {
      "metric_context": "MedTech",
      "period": "FY 2025",
      "speaker_role": "ceo",
      "quote_text": "Now turning to MedTech, where operational sales for the year grew 5.4%.",
      "scale": "ones",
      "unit": "percent",
      "quote_start_char": 9159,
      "quote_end_char": 9230,
      "comparison_period": "FY 2024",
      "claim_type": "yoy_growth",
      "metric_type": "revenue",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "confidence": 1,
      "speaker": "Joaquin Duato",
      "claim_id": "claim_012",
      "claimed_value_raw": "5.4%",
      "qualifiers": [],
      "claimed_value": 5.4
    },
    {
      "quote_text": "In 2025, we delivered nearly $4 billion in sales, with strong performance in cardiovascular and accelerating momentum across surgery and vision.",
      "gaap_classification": "gaap",
      "speaker_role": "ceo",
      "qualifiers": [
        "nearly"
      ],
      "is_approximate": true,
      "confidence": 1,
      "claim_type": "absolute",
      "quote_end_char": 9375,
      "unit": "dollars",
      "metric_context": "MedTech",
      "speaker": "Joaquin Duato",
      "claim_id": "claim_013",
      "period": "FY 2025",
      "scale": "billions",
      "claimed_value": 4,
      "claimed_value_raw": "$4 billion",
      "quote_start_char": 9231,
      "metric_type": "revenue"
    },
    {
      "confidence": 1,
      "scale": "ones",
      "metric_context": "Cardiovascular",
      "claim_id": "claim_014",
      "speaker_role": "ceo",
      "gaap_classification": "gaap",
      "quote_end_char": 9732,
      "is_approximate": false,
      "comparison_period": "FY 2024",
      "quote_text": "Johnson & Johnson today is a leader in three cardiovascular segments, with the portfolio delivering 15% operational sales growth in the year.",
      "unit": "percent",
      "claimed_value": 15,
      "claimed_value_raw": "15%",
      "speaker": "Joaquin Duato",
      "metric_type": "revenue",
      "qualifiers": [],
      "claim_type": "yoy_growth",
      "period": "FY 2025",
      "quote_start_char": 9591
    },
    {
      "qualifiers": [],
      "speaker": "Joaquin Duato",
      "is_approximate": false,
      "claim_id": "claim_015",
      "claim_type": "yoy_growth",
      "claimed_value_raw": "5.3%",
      "claimed_value": 5.3,
      "unit": "percent",
      "quote_text": "And finally, vision, which delivered robust annual operational sales growth of 5.3% with particularly strong momentum in surgical vision.",
      "confidence": 1,
      "scale": "ones",
      "quote_end_char": 11392,
      "comparison_period": "FY 2024",
      "quote_start_char": 11255,
      "metric_context": "Vision",
      "metric_type": "revenue",
      "gaap_classification": "gaap",
      "speaker_role": "ceo",
      "period": "FY 2025"
    },
    {
      "confidence": 1,
      "quote_text": "Starting with Q4 2025 sales results. Worldwide sales were $24.6 billion for the quarter.",
      "quote_end_char": 12320,
      "qualifiers": [],
      "unit": "dollars",
      "claim_id": "claim_016",
      "speaker_role": "management",
      "metric_type": "revenue",
      "claimed_value_raw": "$24.6 billion",
      "scale": "billions",
      "metric_context": "Total",
      "is_approximate": false,
      "claim_type": "absolute",
      "quote_start_char": 12232,
      "period": "Q4 2025",
      "gaap_classification": "gaap",
      "claimed_value": 24.6,
      "speaker": "Darren Snellgrove"
    },
    {
      "claim_type": "yoy_growth",
      "gaap_classification": "gaap",
      "claimed_value": 7.1,
      "is_approximate": false,
      "quote_end_char": 12404,
      "speaker": "Darren Snellgrove",
      "comparison_period": "Q4 2024",
      "confidence": 1,
      "quote_start_char": 12322,
      "claim_id": "claim_017",
      "scale": "ones",
      "qualifiers": [],
      "metric_context": "Total",
      "claimed_value_raw": "7.1%",
      "period": "Q4 2025",
      "unit": "percent",
      "metric_type": "revenue",
      "speaker_role": "management",
      "quote_text": "Sales increased 7.1% despite an approximate 650 basis point headwind from STELARA."
    },
    {
      "period": "Q4 2025",
      "quote_end_char": 12746,
      "qualifiers": [],
      "claim_id": "claim_018",
      "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago.",
      "metric_context": "Total",
      "speaker": "Darren Snellgrove",
      "speaker_role": "management",
      "scale": "billions",
      "claim_type": "absolute",
      "confidence": 1,
      "unit": "dollars",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "metric_type": "net_income",
      "claimed_value_raw": "$5.1 billion",
      "quote_start_char": 12633,
      "claimed_value": 5.1
    },
    {
      "qualifiers": [],
      "metric_type": "eps_diluted",
      "scale": null,
      "claim_id": "claim_019",
      "speaker": "Darren Snellgrove",
      "confidence": 1,
      "claimed_value_raw": "$2.1",
      "is_approximate": false,
      "unit": "per_share",
      "quote_text": "For the quarter, net earnings were $5.1 billion, and diluted earnings per share was $2.1 versus $1.41 a year ago.",
      "claimed_value": 2.1,
      "quote_start_char": 12633,
      "quote_end_char": 12746,
      "speaker_role": "management",
      "gaap_classification": "gaap",
      "metric_context": "Total",
      "period": "Q4 2025",
      "claim_type": "absolute"
    },
    {
      "qualifiers": [
        "Adjusted"
      ],
      "claimed_value_raw": "$6 billion",
      "period": "Q4 2025",
      "quote_end_char": 12904,
      "quote_start_char": 12748,
      "claim_type": "absolute",
      "speaker": "Darren Snellgrove",
      "metric_context": "Total",
      "scale": "billions",
      "speaker_role": "management",
      "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
      "confidence": 1,
      "unit": "dollars",
      "claim_id": "claim_020",
      "is_approximate": false,
      "claimed_value": 6,
      "metric_type": "net_income",
      "gaap_classification": "non_gaap"
    },
    {
      "speaker": "Darren Snellgrove",
      "metric_type": "eps_diluted",
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "claimed_value_raw": "$2.46",
      "period": "Q4 2025",
      "quote_text": "Adjusted net earnings for the quarter were $6 billion, and adjusted diluted earnings per share of $2.46, representing an increase of 21.5% compared to 2024.",
      "confidence": 1,
      "qualifiers": [
        "adjusted"
      ],
      "claim_id": "claim_021",
      "scale": null,
      "speaker_role": "management",
      "quote_end_char": 12904,
      "claim_type": "absolute",
      "quote_start_char": 12748,
      "unit": "per_share",
      "is_approximate": false,
      "claimed_value": 2.46
    },
    {
      "claim_id": "claim_022",
      "claimed_value": 94.2,
      "period": "FY 2025",
      "metric_type": "revenue",
      "unit": "dollars",
      "quote_start_char": 13071,
      "is_approximate": false,
      "confidence": 1,
      "claim_type": "absolute",
      "qualifiers": [],
      "quote_end_char": 13130,
      "scale": "billions",
      "metric_context": "Total",
      "quote_text": "For the full year 2025, worldwide sales were $94.2 billion.",
      "claimed_value_raw": "$94.2 billion",
      "speaker_role": "management",
      "speaker": "Darren Snellgrove",
      "gaap_classification": "gaap"
    },
    {
      "speaker": "Darren Snellgrove",
      "claimed_value_raw": "$10.79",
      "metric_context": "Total",
      "claim_id": "claim_023",
      "qualifiers": [
        "adjusted"
      ],
      "period": "FY 2025",
      "unit": "per_share",
      "speaker_role": "management",
      "quote_start_char": 13857,
      "gaap_classification": "non_gaap",
      "confidence": 1,
      "claim_type": "absolute",
      "metric_type": "eps_diluted",
      "quote_end_char": 14031,
      "quote_text": "Full-year 2025 adjusted net earnings were $26.2 billion, and adjusted diluted earnings per share was $10.79, both representing an increase of 8.1% compared to full year 2024.",
      "is_approximate": false,
      "scale": null,
      "claimed_value": 10.79
    },
    {
      "confidence": 1,
      "scale": "billions",
      "claimed_value": 15.8,
      "is_approximate": false,
      "quote_end_char": 14434,
      "gaap_classification": "gaap",
      "period": "Q4 2025",
      "claim_id": "claim_025",
      "metric_context": "Innovative Medicine",
      "quote_start_char": 14216,
      "metric_type": "revenue",
      "claim_type": "absolute",
      "claimed_value_raw": "$15.8 billion",
      "speaker": "Darren Snellgrove",
      "speaker_role": "management",
      "qualifiers": [],
      "unit": "dollars",
      "quote_text": "Beginning with innovative medicine, worldwide sales of $15.8 billion increased 7.9% despite an approximate 1110 basis point headwind from STELARA, illustrating the continued strength of our key brands and new launches."
    },
    {
      "confidence": 1,
      "quote_text": "Carvictee achieved sales of $555 million with growth of 63.2%, driven by share gains and site expansion.",
      "claimed_value_raw": "$555 million",
      "unit": "dollars",
      "claim_id": "claim_026",
      "claimed_value": 555,
      "quote_start_char": 14883,
      "metric_type": "revenue",
      "qualifiers": [],
      "metric_context": "Carvictee",
      "speaker_role": "management",
      "speaker": "Darren Snellgrove",
      "is_approximate": false,
      "claim_type": "absolute",
      "period": "Q4 2025",
      "gaap_classification": "gaap",
      "quote_end_char": 14987,
      "scale": "millions"
    },
    {
      "metric_context": "Ribrovant plus Lascluse",
      "metric_type": "revenue",
      "scale": "millions",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "period": "Q4 2025",
      "qualifiers": [],
      "claimed_value_raw": "$216 million",
      "quote_text": "In lung cancer, Ribrovant plus Lascluse delivered sales of $216 million and growth of 76.5%, driven by continued launch uptake in all regions.",
      "quote_start_char": 15261,
      "claim_type": "absolute",
      "speaker_role": "management",
      "claim_id": "claim_027",
      "quote_end_char": 15403,
      "unit": "dollars",
      "speaker": "Darren Snellgrove",
      "confidence": 1,
      "claimed_value": 216
    },
    {
      "claimed_value_raw": "$8.8 billion",
      "claim_id": "claim_028",
      "claim_type": "absolute",
      "speaker": "Darren Snellgrove",
      "speaker_role": "management",
      "confidence": 1,
      "metric_context": "MedTech",
      "unit": "dollars",
      "quote_start_char": 16131,
      "scale": "billions",
      "metric_type": "revenue",
      "gaap_classification": "gaap",
      "qualifiers": [],
      "period": "Q4 2025",
      "is_approximate": false,
      "quote_end_char": 16351,
      "claimed_value": 8.8,
      "quote_text": "Now moving to medtech. Worldwide sales of $8.8 billion increased 5.8%, with growth of 6.6% in the US and 4.9% outside of the US, driven by strong performance in our three focus areas: cardiovascular, surgery, and vision."
    },
    {
      "is_approximate": false,
      "claimed_value": 19.7,
      "metric_type": "free_cash_flow",
      "gaap_classification": "unknown",
      "quote_start_char": 22059,
      "quote_end_char": 22216,
      "scale": "billions",
      "qualifiers": [],
      "period": "FY 2025",
      "quote_text": "The company generated $19.7 billion of free cash flow during 2025, on par with 2024 despite increased capital investment in the US and the impact of tariffs.",
      "speaker_role": "cfo",
      "metric_context": "Total",
      "speaker": "Joe Wolk",
      "claim_id": "claim_029",
      "claimed_value_raw": "$19.7 billion",
      "claim_type": "absolute",
      "unit": "dollars",
      "confidence": 1
    },
    {
      "metric_type": "revenue",
      "confidence": 1,
      "claim_type": "guidance",
      "speaker_role": "cfo",
      "period": "FY 2026",
      "claimed_value_raw": "5.7%",
      "scale": "ones",
      "quote_end_char": 22785,
      "claimed_value": 5.7,
      "speaker": "Joe Wolk",
      "is_approximate": false,
      "metric_context": "Total",
      "unit": "percent",
      "gaap_classification": "gaap",
      "qualifiers": [],
      "quote_text": "Turning now to guidance for the full year 2026. We anticipate operational sales growth in the range of 5.7% to 6.7% with a midpoint of $100 billion or 6.2%.",
      "quote_start_char": 22629,
      "claim_id": "claim_030"
    },
    {
      "metric_context": "Total",
      "claim_type": "guidance",
      "quote_end_char": 25428,
      "period": "FY 2026",
      "claim_id": "claim_032",
      "scale": null,
      "metric_type": "eps_diluted",
      "claimed_value_raw": "$11.53",
      "is_approximate": false,
      "quote_text": "As such, we expect reported adjusted earnings per share of $11.53 at the midpoint.",
      "gaap_classification": "non_gaap",
      "quote_start_char": 25346,
      "qualifiers": [
        "reported adjusted",
        "midpoint"
      ],
      "unit": "per_share",
      "speaker_role": "cfo",
      "speaker": "Joe Wolk",
      "claimed_value": 11.53,
      "confidence": 1
    }
  ],
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 4,
  "extracted_at": "2026-02-13T11:47:34.614289"
}